Challenge
A small biotech developing bentracimab, a novel biologic, received a Complete Response Letter that raised CMC findings against its BLA.
Approach
NGT led the regulatory resubmission, addressed the CMC findings in the response, and prepared the company for its interaction with the health authority.
Outcome
The program secured a positive Type A meeting result, moving the biologic back onto a forward path.
Disciplines involved